A Study on TAK-279 for Ulcerative Colitis
Phase 2
207
about 3.4 years
18–75
16 sites in CA, FL, GA +7
What this study is about
Researchers are testing whether TAK-279 can reduce bowel inflammation and symptoms in people with moderately to severely active ulcerative colitis. The trial also compares any medical problems that participants experience when taking TAK-279 or a placebo, and how well they tolerate these problems.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take TAK-279
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Change From Baseline in Disease-Specific Health-related Quality of Life (HRQoL) as Measured by IBDQ Total Score at Week 12, Change From Baseline in Fatigue as Measured by the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) Score at Week 12, Percentage of Participants With no Abdominal Pain at Week 12
Gastroenterology